You can install PPMD to make it easier to access on your device. A network connection is still required to view medication and interaction information.
You should now see a icon on your home screen.
Tap then menu button, and then tap Install.
Not all web browsers and platforms support progressive web applications (PWA). Consult the documentation for your web browser for additional assistance.
N/A
This was an open-label, 3-period, fixed-sequence drug-interaction study in thirteen healthy adult subjects. In Period 1, a single dose (SD) of a doravirine 100mg tablet was administered. In Period 2, a SD of a doravirine 100mg tablet was coadministered with a SD of 20mL of an antacid suspension containing 1600mg of each aluminum hydroxide and magnesium hydroxide and 160mg of simethicone. In Period 3, a pantoprazole sodium 40mg delayed-release tablet was administered on Days 1-5 and a SD of a doravirine 100mg tablet was administered on Day 5. There was a washout of 10 days between each period. Blood samples to measure doravirine plasma concentrations were collected predose and through 72 hours post dose in all periods.
Following co-administration with an aluminum/magnesium containing antacid, doravirine PK was not affected to a clinical meaningful extent. The geometric mean ratios (GMR) (90% confidence intervals) [doravirine + antacid/doravirine] for Cmax, AUC0-∞, and C24 were 0.86 (0.74,1.01), 1.01 (0.92,1.11), and 1.03 (0.94,1.12), respectively. Following co-administration with pantoprazole, there was no clinically significant effect on doravirine PK. The GMR (90% confidence intervals) [doravirine + pantoprazole/ doravirine] for Cmax, AUC0-∞, and C24 were 0.88 (0.76,1.01), 0.83 (0.76,0.91), and 0.84 (0.77, 0.92), respectively. There were no serious adverse experiences (AEs) and all AEs were mild in intensity. Overall, 3 (21%) subjects reported at least one AE during the study. The most common AE was headache reported by 3 subjects.
The authors concluded that doravirine is generally well tolerated when administered alone or with an aluminum/magnesium containing antacid or with the proton pump inhibitor, pantoprazole. Coadministration of either of these agents with doravirine does not have a clinically meaningful effect on doravirine PK.
Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Deschamps K, Fan L. Co-administration of doravirine with an aluminum/magnesium containing antacid or pantoprazole, a proton pump inhibitor, does not have a clinically meaningful effect on doravirine pharmacokinetics . International Aids Society Conference On Hiv Science. Paris, France. 9; July 2017.